Roche announced three-year follow-up data from the pivotal phase III STARGLO study in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback